Published in J Biol Chem on May 16, 2008
Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One (2008) 2.65
Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J Biol Chem (2009) 1.28
The supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration. Orphanet J Rare Dis (2014) 1.23
Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J Biol Chem (2014) 1.19
Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology (2008) 1.19
Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One (2009) 1.18
Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res (2010) 1.16
WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol (2010) 1.16
The tumour suppressor gene WWOX is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. Brain (2013) 1.14
Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One (2009) 1.05
Identification of IGF1, SLC4A4, WWOX, and SFMBT1 as hypertension susceptibility genes in Han Chinese with a genome-wide gene-based association study. PLoS One (2012) 1.03
Tumor suppressor WWOX binds to ΔNp63α and sensitizes cancer cells to chemotherapy. Cell Death Dis (2013) 1.02
Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation. Cell Death Differ (2014) 1.00
Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Hum Mol Genet (2010) 0.98
Zfra is a small wizard in the mitochondrial apoptosis. Aging (Albany NY) (2010) 0.97
Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia. Genes Cancer (2011) 0.96
Common Chromosomal Fragile Site Gene WWOX in Metabolic Disorders and Tumors. Int J Biol Sci (2014) 0.95
Biophysical basis of the binding of WWOX tumor suppressor to WBP1 and WBP2 adaptors. J Mol Biol (2012) 0.93
Common fragile site tumor suppressor genes and corresponding mouse models of cancer. J Biomed Biotechnol (2010) 0.93
Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype. J Cell Physiol (2013) 0.91
WWOX gene is associated with HDL cholesterol and triglyceride levels. BMC Med Genet (2010) 0.88
Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med Genomics (2013) 0.88
The cancer gene WWOX behaves as an inhibitor of SMAD3 transcriptional activity via direct binding. BMC Cancer (2013) 0.87
WWOX expression in colorectal cancer--a real-time quantitative RT-PCR study. Tumour Biol (2011) 0.87
Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma. Chin J Cancer (2014) 0.86
Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep (2015) 0.85
The tumor suppressor WW domain-containing oxidoreductase modulates cell metabolism. Exp Biol Med (Maywood) (2014) 0.85
Molecular origin of the binding of WWOX tumor suppressor to ErbB4 receptor tyrosine kinase. Biochemistry (2013) 0.85
Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer. Oncol Lett (2014) 0.82
The WWOX gene modulates high-density lipoprotein and lipid metabolism. Circ Cardiovasc Genet (2014) 0.82
Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders. Curr Osteoporos Rep (2014) 0.82
Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells. J Biol Chem (2015) 0.82
Histone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferases. Crit Rev Biochem Mol Biol (2014) 0.80
Diverse effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines. Tumour Biol (2014) 0.80
Alteration of WWOX in human cancer: a clinical view. Exp Biol Med (Maywood) (2015) 0.80
Regulation of cell signaling and apoptosis by tumor suppressor WWOX. Exp Biol Med (Maywood) (2015) 0.80
Role of WWOX and NF-κB in lung cancer progression. Transl Respir Med (2013) 0.79
WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma. Cancer Res (2016) 0.79
Functions and Epigenetic Regulation of Wwox in Bone Metastasis from Breast Carcinoma: Comparison with Primary Tumors. Int J Mol Sci (2017) 0.78
Genome-wide QTL mapping of nine body composition and bone mineral density traits in pigs. Genet Sel Evol (2014) 0.78
WWOX, large common fragile site genes, and cancer. Exp Biol Med (Maywood) (2015) 0.78
Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer. Exp Biol Med (Maywood) (2014) 0.77
Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase. Exp Biol Med (Maywood) (2014) 0.77
Loss of wwox expression in zebrafish embryos causes edema and alters Ca(2+) dynamics. PeerJ (2015) 0.77
WWOX loss activates aerobic glycolysis. Mol Cell Oncol (2014) 0.75
Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma. Exp Biol Med (Maywood) (2014) 0.75
Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet (2016) 0.75
WWOX guards genome stability by activating ATM. Mol Cell Oncol (2015) 0.75
WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response. Cell Death Dis (2017) 0.75
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 5.56
WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res (2000) 4.07
The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer (2005) 3.59
Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell (2005) 3.26
Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr (2004) 2.81
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
Regulation of chondrocyte differentiation by Cbfa1. Mech Dev (1999) 2.73
Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science (2006) 2.70
Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet (2000) 2.56
FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev (2002) 2.41
Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A (2007) 2.37
E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem (2003) 2.34
Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res (2003) 2.20
BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network. J Biol Chem (2006) 2.15
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res (2001) 2.12
Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J (2004) 2.12
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev (2006) 2.04
The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem (2005) 1.93
WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res (2005) 1.91
Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A (2004) 1.91
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A (2005) 1.83
Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res (2004) 1.74
Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. Mol Cell Biol (1999) 1.72
Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol (2003) 1.69
WWOX in biological control and tumorigenesis. J Cell Physiol (2007) 1.66
WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene (2004) 1.47
WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med (2006) 1.44
The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab (2003) 1.38
Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. Endocrinology (1996) 1.28
Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res (2006) 1.21
Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Res (2007) 1.19
PKA-mediated protein phosphorylation regulates ezrin-WWOX interaction. Biochem Biophys Res Commun (2006) 1.14
WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy. Genes Chromosomes Cancer (2007) 1.13
TSH and bone loss. Ann N Y Acad Sci (2006) 1.12
Bone defects in latent TGF-beta binding protein (Ltbp)-3 null mice; a role for Ltbp in TGF-beta presentation. J Endocrinol (2002) 1.10
The relationship between the GH/IGF-I axis and serum markers of bone turnover metabolism in healthy children. Eur J Endocrinol (2007) 1.07
Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol (2003) 1.04
Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J Bone Miner Res (2003) 0.99
Osteopetrosis-like phenotype in latent TGF-beta binding protein 3 deficient mice. Bone (2005) 0.98
Isoform-specific regulation of platelet-derived growth factor activity and binding in osteoblast-enriched cultures from fetal rat bone. J Clin Invest (1992) 0.86
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
MicroRNAs in Cancer. Annu Rev Med (2009) 9.37
Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell (2009) 8.62
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
MicroRNA expression and function in cancer. Trends Mol Med (2006) 7.02
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol Cell Biol (2006) 5.74
Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res (2006) 5.72
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A (2005) 5.54
Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A (2005) 5.53
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Crystal structures of Tcl1 family oncoproteins and their conserved surface features. ScientificWorldJournal (2002) 5.20
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A (2002) 4.86
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
The Lin28/let-7 axis regulates glucose metabolism. Cell (2011) 4.65
NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell (2008) 4.57
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A (2011) 4.11
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A (2007) 4.06
MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol (2007) 4.02
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell (2008) 4.01
Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem (2005) 3.97
Extra-embryonic function of Rb is essential for embryonic development and viability. Nature (2003) 3.92
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem (2009) 3.62
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52